Objective
The aim of this research is to exploit technology for nucleic acid delivery through the clinical testing of adoptive engineered T cells to treat cancer. Recent innovative developments in cancer gene-immunotherapy have led to very encouraging early clinical results. However, the use of engineered T cells is a challenging and complex field with further development and more proof-of-principle trials needed. This proposal builds upon previous EU funded pre-clinical projects and comprises a multidisciplinary and translational research group with wide-ranging relevant expertise. Building on encouraging clinical results targeting NY-ESO-1 in melanoma and the availability of clinical grade vector, the consortium proposes to rapidly initiate two landmark studies in this field: the first to examine the activity of engineered T cells in oesophago-gastric cancer as an example of a hard to treat common epithelial cancer; the second to undertake a randomised phase II study to determine whether an optimised cell production system developed by the partners improves the current clinical response rates in patients with metastatic melanoma treated with NY-ESO-1 targeted T-cells. Success in these trials will enable the consortia and others to carryout larger trials and potentially approval of this type of therapy as a treatment for multiple cancer types. The inclusion of a major industrial partner focused on cell therapy technology and two SMEs focus on the delivery of cell therapy will facilitate future development of this area following these trials; indeed the project also includes plans to further automate and streamline cell processing to facilitate this development. This project would enhance European expertise and competitiveness in an important emerging market. The research will also support the European biotechnology industry which will be important for the exploitation of these therapies and the successful outcome of this project.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
- medical and health sciencesmedical biotechnologycells technologies
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Call for proposal
FP7-HEALTH-2012-INNOVATION-1
See other projects for this call
Funding Scheme
CP-FP - Small or medium-scale focused research projectCoordinator
M13 9PL Manchester
United Kingdom
See on map
Participants (15)
3015 GD Rotterdam
See on map
17177 Stockholm
See on map
Participation ended
20132 Milano
See on map
M20 4BX Manchester
See on map
75654 Paris
See on map
M13 9XX Manchester
See on map
NW3 2QG London
See on map
51429 Bergish Gladbach
See on map
1066 CX Amsterdam
See on map
1066EC Amsterdam
See on map
OX4 2HN OXFORD
See on map
NW1 2PG London
See on map
104 22 Stockholm
See on map
WC1E 6BT LONDON
See on map
20132 Milano
See on map